Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Lipocine (LPCN) over the last 11 years, with Q3 2025 value amounting to $115272.0.

  • Lipocine's Receivables - Other rose 2600.51% to $115272.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $115272.0, marking a year-over-year increase of 2600.51%. This contributed to the annual value of $120447.0 for FY2024, which is 13050.29% up from last year.
  • Lipocine's Receivables - Other amounted to $115272.0 in Q3 2025, which was up 2600.51% from $121732.0 recorded in Q2 2025.
  • In the past 5 years, Lipocine's Receivables - Other ranged from a high of $579428.0 in Q3 2022 and a low of $52254.0 during Q4 2023
  • For the 5-year period, Lipocine's Receivables - Other averaged around $224639.2, with its median value being $130505.0 (2023).
  • In the last 5 years, Lipocine's Receivables - Other surged by 6313606.14% in 2021 and then tumbled by 9098.18% in 2023.
  • Lipocine's Receivables - Other (Quarter) stood at $247253.0 in 2021, then skyrocketed by 134.35% to $579428.0 in 2022, then tumbled by 90.98% to $52254.0 in 2023, then skyrocketed by 130.5% to $120447.0 in 2024, then dropped by 4.3% to $115272.0 in 2025.
  • Its last three reported values are $115272.0 in Q3 2025, $121732.0 for Q2 2025, and $179027.0 during Q1 2025.